3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
18
Gastrointestinal Stromal Tumors
12
Leukemia, Myeloid, Chronic-Phase
9
Leukemia
7
Leukemia, Myeloid, Acute
6
Blast Crisis
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms
5
Leukemia, Myeloid, Accelerated Phase
5
Gliosarcoma
5
Glioblastoma
5
Brain Neoplasms
5
Glioma
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Prostatic Neoplasms
3
Philadelphia Chromosome
3
Pancreatic Neoplasms
3
Oligodendroglioma
3
Myeloproliferative Disorders
3
Multiple Myeloma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Central Nervous System Neoplasms
3
Astrocytoma
3
Primary Myelofibrosis
2
Pdgfra-Associated Chronic Eosinophilic Leukemia
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Interventions
pembrolizumab
2
tislelizumab
1
Trastuzumab
1
Imatinib Mesylate
1
GSK-3326595
1
Cyclophosphamide
1
Blood Specimen Collection
1
BMS-906024
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Adenoid Cystic
×
Imatinib Mesylate
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled